{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T10:30:59Z","timestamp":1648722659658},"reference-count":87,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Geriatric Medicine"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1016\/j.cger.2005.09.002","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T15:08:25Z","timestamp":1168441705000},"page":"57-74","source":"Crossref","is-referenced-by-count":2,"title":["Antiplatelet Agents and Arterial Thrombosis"],"prefix":"10.1016","volume":"22","author":[{"given":"Henny H.","family":"Billett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cger.2005.09.002_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/heart.85.3.265","article-title":"Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta analysis of randomized trials","volume":"85","author":"Sanmuganathan","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.cger.2005.09.002_bib2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/00149831-200410000-00006","article-title":"Comparison of cardiovascular risk factors and drug use in 14,544 French patients with a history of myocardial infarction, ischemic stroke and\/or peripheral arterial disease","volume":"11","author":"Borgard","year":"2004","journal-title":"Eur J Cardiovasc Prev Rehab"},{"key":"10.1016\/j.cger.2005.09.002_bib3","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ahj.2003.11.028","article-title":"Effect of age on the use of evidence based therapies for acute myocardial infarction","volume":"148","author":"Tran","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.cger.2005.09.002_bib4","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood.V83.4.885.885","article-title":"Aspirin, platelets and thrombosis: theory and practice","volume":"83","author":"Roth","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.cger.2005.09.002_bib5","doi-asserted-by":"crossref","unstructured":"Patrono C., Coller B., Fitzgerald G.A., et al. Platelet active drugs: the relationships among dose, effectiveness and side effects. In: Hirsch J., Guyatt G., Albers G., et al, editors. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: evidence-based guidelines. Chest 2004;126:234S\u201364S","DOI":"10.1378\/chest.126.3_suppl.234S"},{"key":"10.1016\/j.cger.2005.09.002_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians' Health Study","volume":"321","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2005.09.002_bib7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","article-title":"Randomised trial of prophylactic daily aspirin in British male doctors","volume":"296","author":"Peto","year":"1988","journal-title":"BMJ"},{"key":"10.1016\/j.cger.2005.09.002_bib8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis Prevention Trial. Randomized trial of low intensity oral anticoagulation with warfarin and low dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. MRC General Practice Research Framework","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2005.09.002_bib9","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effect of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomized trial. HOT study group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2005.09.002_bib10","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.2337\/diacare.26.12.3264","article-title":"PPP Collaborative Group Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial","volume":"26","author":"Sacco","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cger.2005.09.002_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-136-2-200201150-00015","article-title":"Aspirin for the primary prevention of cardiovascular events: recommendation and rationale","volume":"136","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cger.2005.09.002_bib12","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1001\/archinte.163.17.2006","article-title":"An update on aspirin in the primary prevention of cardiovascular disease","volume":"163","author":"Eidelman","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cger.2005.09.002_bib13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/00004872-200018050-00017","article-title":"Influence of gender and age on preventing cardiovascular disease by antihypertensive treatments and acetylsalicylic acid. The HOT Study","volume":"18","author":"Kjeldsen","year":"2000","journal-title":"J Hypertens"},{"key":"10.1016\/j.cger.2005.09.002_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1076-7460.2003.02012.x","article-title":"Elderly patients with acute coronary syndromes; higher risk and greater benefit from antiplatelet therapy and\/or interventional therapies","volume":"12","author":"Cannon","year":"2003","journal-title":"Am J Geriatr Cardiol"},{"key":"10.1016\/j.cger.2005.09.002_bib15","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1345\/aph.1D025","article-title":"Primary prevention of coronary heart disease in the elderly","volume":"37","author":"Dornbrook-Lavender","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cger.2005.09.002_bib16","first-page":"349","article-title":"Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2005.09.002_bib17","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"The International Stroke Trial: a randomized trial of aspirin, subcutaneous heparin, both or neither among 19,435 patients with acute ischemic stroke","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2005.09.002_bib18","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(97)04010-5","article-title":"Randomized placebo controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2005.09.002_bib19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.cger.2005.09.002_bib20","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa011258","article-title":"A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke","volume":"345","author":"Mohr","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2005.09.002_bib21","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa043033","article-title":"Warfarin aspirin symptomatic intracranial disease trial investigators: comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis","volume":"352","author":"Chimowitz","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2005.09.002_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJMe038191","article-title":"Antiplatelet therapy for ischemic heart disease","volume":"350","author":"Lange","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2005.09.002_bib23","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1161\/01.CIR.0000145172.55640.93","article-title":"Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin","volume":"110","author":"Gage","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cger.2005.09.002_bib24","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(00)02110-3","article-title":"Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2005.09.002_bib25","doi-asserted-by":"crossref","unstructured":"Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism. In: Hirsch J., Guyatt G., Albers G., et al, editors. The seventh ACCP conference on Antithrombotic and thrombolytic therapy: evidence-based guidelines. Chest 2004;126:338S\u2013400S","DOI":"10.1378\/chest.126.3_suppl.338S"},{"key":"10.1016\/j.cger.2005.09.002_bib26","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000114834.85476.81","article-title":"Evidence based guidelines for cardiovascular disease prevention in women","volume":"109","author":"Mosca","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cger.2005.09.002_bib27","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low dose ASA in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2005.09.002_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1345\/aph.1E115","article-title":"Analysis of aspirin associated risks in healthy individuals","volume":"39","author":"Hur","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cger.2005.09.002_bib29","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes","volume":"108","author":"Peters","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cger.2005.09.002_bib30","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199110313251801","article-title":"A comparison of two doses of aspirin in patients after a transient ischemic attack or minor ischemic stroke","volume":"325","author":"Dutch","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2005.09.002_bib31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.7326\/0003-4819-130-1-199901050-00004","article-title":"Frequency of major complications of aspirin, warfarin and intravenous heparin for secondary stroke prevention","volume":"130","author":"Petty","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cger.2005.09.002_bib32","first-page":"571","article-title":"Salicylate metabolism: effects of age and sex in adults","volume":"39","author":"Montgomery","year":"1986","journal-title":"Clin Pharmacother"},{"key":"10.1016\/j.cger.2005.09.002_bib33","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/00004872-200018050-00017","article-title":"Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study","volume":"18","author":"Kjeldsen","year":"2000","journal-title":"J Hypertens"},{"key":"10.1016\/j.cger.2005.09.002_bib34","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/S0140-6736(99)05388-X","article-title":"low dose and high dose ASA for patients undergoing carotid endarterectomy: a randomized controlled trial","volume":"353","author":"Taylor","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2005.09.002_bib35","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1538-7836.2005.01119.x","article-title":"Variability in response to aspirin: do we understand the clinical relevance","volume":"3","author":"Campbell","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cger.2005.09.002_bib36","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1067\/mhj.2001.113994","article-title":"Prior aspirin users with acute non-ST elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin","volume":"141","author":"Santopinto","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.cger.2005.09.002_bib37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/107602960100700305","article-title":"Individual dosing of aspirin prophylaxis by controlling platelet aggregation","volume":"7","author":"Syrebe","year":"2001","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.cger.2005.09.002_bib38","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jacc.2003.08.062","article-title":"Inhibition of platelet aggregation by aspirin progressively decreases in long term treated patients","volume":"43","author":"Pulcinelli","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cger.2005.09.002_bib39","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1161\/01.STR.25.12.2331","article-title":"Development of aspirin resistance in persons with previous ischemic stroke","volume":"25","author":"Helgason","year":"1994","journal-title":"Stroke"},{"key":"10.1016\/j.cger.2005.09.002_bib40","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-142-5-200503010-00012","article-title":"Narrative review: aspirin resistance and its clinical implications","volume":"142","author":"Sanderson","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cger.2005.09.002_bib41","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/00004872-199917070-00022","article-title":"Compliance with aspirin or placebo in the hypertension optimal treatment study","volume":"17","author":"Waeber","year":"1999","journal-title":"J Hypertens"},{"key":"10.1016\/j.cger.2005.09.002_bib42","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1046\/j.1538-7836.2003.00284.x","article-title":"Aspirin resistance: definition, mechanisms and clinical read-outs","volume":"1","author":"Patrono","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cger.2005.09.002_bib43","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1055\/s-0037-1613805","article-title":"Monitoring of aspirin pharmacodynamics with the PFA-100","volume":"83","author":"Homoncik","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cger.2005.09.002_bib44","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jacc.2004.01.022","article-title":"Aspirin resistance: more than just a laboratory curiosity","volume":"43","author":"Bhatt","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cger.2005.09.002_bib45","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0049-3848(93)90164-J","article-title":"Two year follow up of aspirin responders and aspirin non-responders: a pilot study including 180 post-stroke patients","volume":"71","author":"Grotemeyer","year":"1993","journal-title":"Thromb Res"},{"key":"10.1016\/j.cger.2005.09.002_bib46","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00415-003-0954-y","article-title":"Aspirin nonresponder status in patients with recurrent cerebral ischemic attacks","volume":"250","author":"Grundman","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.cger.2005.09.002_bib47","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","article-title":"A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease","volume":"41","author":"Gum","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cger.2005.09.002_bib48","first-page":"2048","article-title":"Aspirin resistance: a new independent predictor of vascular events","volume":"1","author":"Eikelboom","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cger.2005.09.002_bib49","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","article-title":"Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events","volume":"105","author":"Eikelboom","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cger.2005.09.002_bib50","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cger.2005.09.002_bib51","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1161\/01.CIR.0000015422.86569.52","article-title":"Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?","volume":"105","author":"Halushka","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cger.2005.09.002_bib52","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/01.CIR.0000081770.51929.5A","article-title":"Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery","volume":"108","author":"Zimmermann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cger.2005.09.002_bib53","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2005.09.002_bib54","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1161\/01.CIR.0000087593.07533.9B","article-title":"Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal anti-inflammatory drugs","volume":"108","author":"Kurth","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cger.2005.09.002_bib55","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7326\/0003-4819-142-7-200504050-00113","article-title":"The risk for myocardial infarction with cyclooxygenase \u20132 inhibitors: a population of elderly adults","volume":"142","author":"Levesque","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cger.2005.09.002_bib56","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2005.09.002_bib57","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.jacc.2003.12.034","article-title":"Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous intervention despite clopidogrel treatment","volume":"43","author":"Chen","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cger.2005.09.002_bib58","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1055\/s-0038-1646487","article-title":"Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate","volume":"66","author":"Cattaneo","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cger.2005.09.002_bib59","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1161\/01.ATV.20.10.2316","article-title":"Acute antithrombotic effect of a front loaded regimen of clopidogrel in patients with atherosclerosis on aspirin","volume":"20","author":"Helft","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cger.2005.09.002_bib60","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.0306-5251.2001.01453.x","article-title":"Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers","volume":"52","author":"Weber","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cger.2005.09.002_bib61","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200006153422402","article-title":"TTP associated with clopidogrel","volume":"342","author":"Bennett","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2005.09.002_bib62","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cger.2005.09.002_bib63","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomized, blinded trial of clopidogrel v. aspirin in patients at risk of ischemic events","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2005.09.002_bib64","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2005.09.002_bib65","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1111\/j.1538-7836.2004.01017.x","article-title":"A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following MI: the CADET Trial","volume":"2","author":"Woodward","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cger.2005.09.002_bib66","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with non-ST segment elevation acute coronary syndromes","volume":"345","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2005.09.002_bib67","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Clarity \u2013TIMI","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2005.09.002_bib68","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cger.2005.09.002_bib69","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2005.09.002_bib70","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cger.2005.09.002_bib71","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction","volume":"109","author":"Matetzky","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cger.2005.09.002_bib72","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1111\/j.1538-7836.2004.01046.x","article-title":"Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100","volume":"2","author":"Raman","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cger.2005.09.002_bib73","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1538-7836.2004.01063.x","article-title":"Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases","volume":"3","author":"Aleil","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cger.2005.09.002_bib74","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1001\/archneur.62.3.403","article-title":"Efficacy of aspirin plus extended release dipyridamole in preventing recurrent stroke in high risk populations","volume":"62","author":"Sacco","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cger.2005.09.002_bib75","first-page":"S1","article-title":"European Stroke Prevention Study. 2. Efficacy and safety data","volume":"15S","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.cger.2005.09.002_bib76","first-page":"956","article-title":"Platelet GPIIb IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization","volume":"36","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2005.09.002_bib77","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","article-title":"Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade. Evaluation of Platelet IIb\/IIIa Inhibitor for Stenting","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2005.09.002_bib78","doi-asserted-by":"crossref","first-page":"23C","DOI":"10.1016\/S0002-9149(00)00876-6","article-title":"IIb's are not IIb's","volume":"85","author":"Kereiakes","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cger.2005.09.002_bib79","doi-asserted-by":"crossref","first-page":"S287","DOI":"10.1053\/hj.1999.v138.a100461","article-title":"Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors","volume":"138","author":"Blankenship","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.cger.2005.09.002_bib80","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of monoclonal antibody directed against the platelet GPIIb IIIa receptor in high risk coronary angioplasty","volume":"330","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2005.09.002_bib81","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0735-1097(00)00688-4","article-title":"Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy","volume":"36","author":"Sane","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cger.2005.09.002_bib82","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1182\/blood-2002-11-3566","article-title":"Desmopressin antagonizes the in-vitro platelet dysfunction induced by GPIIb IIIa inhibitors and aspirin","volume":"102","author":"Reiter","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cger.2005.09.002_bib83","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/euhj.2001.2736","article-title":"Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb\/IIIa receptor blocker","volume":"23","author":"Ronner","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cger.2005.09.002_bib84","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0735-1097(98)00130-2","article-title":"Modifiable risk factors for vascular access site complications of angioplasty with glycoprotein IIb\/IIIa receptor inhibition in the impact II trial","volume":"31","author":"Mandak","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cger.2005.09.002_bib85","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1345\/aph.1E048","article-title":"Evaluation of bleeding complications associated with GPIIb IIIa inhibitors","volume":"38","author":"Brouse","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cger.2005.09.002_bib86","first-page":"1498","article-title":"A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2005.09.002_bib87","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(00)05059-5","article-title":"Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet GPIIb IIIa inhibition. The GUSTO V randomized trial","volume":"357","author":"Topol","year":"2001","journal-title":"Lancet"}],"container-title":["Clinics in Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069005000686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069005000686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T17:47:22Z","timestamp":1587318442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749069005000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S0749069005000686"],"URL":"https:\/\/doi.org\/10.1016\/j.cger.2005.09.002","relation":{},"ISSN":["0749-0690"],"issn-type":[{"value":"0749-0690","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}